MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 29736023.
- Also identified by DOI 10.1038/s41591-018-0015-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Genetic defects underlying the melanocortin-4 receptor (MC4R) signaling pathway lead to severe obesity. Three severely obese LEPR-deficient individuals were administered the MC4R agonist setmelanotide, resulting in substantial and durable reductions in hyperphagia and body weight over an observation period of 45-61 weeks. Compared to formerly developed and tested MC4R agonists, setmelanotide has the unique capability of activating nuclear factor of activated T cell (NFAT) signaling and restoring function of this signaling pathway for selected MC4R variants. Our data demonstrate the potency of setmelanotide in treatment of individuals with diverse MC4R-related pathway deficiencies.
Medical subject headings
- Receptor, Melanocortin, Type 4
- Receptors, Leptin
- Weight Loss